指南与共识泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

COVID-19疫情期间前列腺癌放疗建议

Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19.
指南 / 共识 · Adv Radiat Oncol · 2020-10-29

美国与英国放射肿瘤学家快速系统综述并达成共识,提出RADS框架(远程访视、避免、推迟和缩短放疗)用于前列腺癌管理。建议按NCCN风险组分层:极低/低/有利中危可避免或延迟放疗;不利中危/高危/临床淋巴结阳性/术后复发/寡转移/低体积M1可先行4-6月新辅助激素治疗;局限/寡转移/低体积M1优先超分割,术后及临床淋巴结阳性优先中度分割;挽救放疗优于辅助放疗。

要点

  • RADS框架适用于前列腺癌各分期,可减少资源使用。
  • 极低/低/有利中危可避免或延迟放疗至安全时。
  • 不利中危/高危/临床淋巴结阳性/术后复发/寡转移/低体积M1可新辅助激素治疗4-6月。

核心结论

  • 所有已识别的 prostate cancer 分期均可减少资源使用,RADS框架可推广至其他病种。

研究设计与样本

  • 美国与英国放射肿瘤学家快速开展系统综述并达成共识,创建RADS框架。

主要发现

  • 按NCCN风险组提供临床淋巴结阳性、术后、寡转移和低体积M1疾病的建议。
  • 所有分期推荐远程会诊和复诊(资源/人员允许时)。
  • 根据分期,会诊和复诊延迟1至6个月被视为安全。
  • 极低、低和有利中危可避免或延迟放疗至安全时。
  • 不利中危、高危、临床淋巴结阳性、术后复发、寡转移和低体积M1可必要时接受4至6月新辅助激素治疗。

关键数值与推荐

  • 局限、寡转移和低体积M1优先超分割放疗。
  • 术后和临床淋巴结阳性优先中度分割放疗。
  • 挽救放疗优于辅助放疗。

临床怎么用

  • 资源/人员允许时采用远程会诊和复诊。
  • 根据分期将会诊和复诊延迟1至6个月。
  • 极低/低/有利中危避免或延迟放疗至安全时。
  • 不利中危/高危/临床淋巴结阳性/术后复发/寡转移/低体积M1可新辅助激素治疗4-6月。
  • 局限/寡转移/低体积M1选超分割,术后/临床淋巴结阳性选中度分割,挽救优于辅助。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. METHODS AND MATERIALS: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. RESULTS: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. CONCLUSIONS: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zaorsky NG, Yu JB, McBride SM, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020. PMID: 33145460. doi:10.1016/j.adro.2020.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。